Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of NTX-101 in Healthy Volunteers
NCT05041543Phase 1Completed
- Sponsor
- PinotBio
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Classical Binding Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NTX-101 in Glaucoma (5 arms), sponsored by PinotBio. Primary endpoint: Incidence, type, and severity of Adverse Events at 7 Days. Started Mar 2021; status: completed.
02
Drugs
NTX-101
03
Conditions
Glaucoma
Beyond the preview
Go deeper on NCT05041543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041543.